|
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
If confirmed in patients, this information might prove useful to monitor clinical response to Met-targeted therapies in MET-amplified gastric carcinomas.
|
21500189 |
2012 |
|
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Moreover, aberrations of MET are associated with EGFR and PTEN signalling and might possess relevance for targeted therapies of salivary gland carcinomas in the future.
|
23242174 |
2013 |
|
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Recently, overexpression of the Met/HGF receptor gene has been detected in fresh samples of carcinomas and in epithelial tumor cell lines but not in cell lines derived from human leukemia and lymphoma.
|
8289471 |
1994 |
|
Carcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Up-regulated expression of Ezrin and c-Met proteins are related to the metastasis and prognosis of gastric carcinomas.
|
21751142 |
2011 |
|
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Overexpression of the hepatocyte growth factor receptor (Met/HGF receptor), a transmembrane tyrosine kinase encoded by the met proto-oncogene, has been associated with tumor progression in different human carcinomas.
|
8863670 |
1996 |
|
Carcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
We analyzed the expression of these genes and the mutations in the kinase domain of the Met gene in 43 gastric carcinomas.
|
10752688 |
2000 |
|
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Identification of MET exon14 skipping by targeted DNA- and RNA-based next-generation sequencing in pulmonary sarcomatoid carcinomas.
|
30032818 |
2018 |
|
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Elevated protein levels in absence of gene amplification were not attributed to mutations, based on results of targeted next-generation sequencing.Our data reveal that clear-cell RCC with MET upregulation show an aggressive behavior and MET copy number increase is evident in a substantial percentage of patients with high-grade carcinomas and metastatic disease.
|
27894094 |
2017 |
|
Carcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The antibodies revealed expression of c-MET protein in hepatomas (11/14), carcinomas of colon and rectum (19/21), stomach (11/22), kidney (16/19), ovary (9/17) and skin (7/17).
|
1917129 |
1991 |
|
Carcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
c-MET Overexpression as a Poor Predictor of MET Amplifications or Exon 14 Mutations in Lung Sarcomatoid Carcinomas.
|
30149144 |
2018 |
|
Carcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Six (55%) of the 11 gastric carcinoma cell lines and 15 (23%) of the 64 advanced gastric carcinomas showed the c-met gene amplification.
|
1333188 |
1992 |
|
Carcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Overexpression of gastrin and c-met protein involved in human gastric carcinomas and intestinal metaplasia.
|
14719064 |
2004 |
|
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Amino acid uptake inhibitor studies were performed in four human carcinoma cells (epidermal carcinoma A431, colorectal carcinoma LS180, and lung carcinomas PC14/GL and H441/GL) using the radioisotope analogs [<sup>3</sup>H]MET and [<sup>14</sup>C]MeAIB.
|
28284101 |
2017 |
|
Carcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Summarizing these and previous results, mutations of the MET proto-oncogene were detected in 17/129 sporadic papillary renal carcinomas but not in other solid tumors.
|
10327054 |
1999 |
|
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
This is the first report to analyze the statuses of the MET gene in ECCs, and the two mixed cases exhibited amplifications that are shared with ovarian clear-cell carcinomas.
|
29633423 |
2018 |
|
Carcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
These results suggest that the amplification and overexpression of c-met gene do not play a different role in the progression and metastasis of EBV-positive and EBV-negative gastric carcinomas.
|
11810045 |
2002 |
|
Carcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
While the prevalence of c-MET mutations and amplifications ranges 0-25%, c-MET upregulation can be found in the majority of squamous head & neck carcinomas.
|
28259294 |
2017 |
|
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Overexpression of the hepatocyte growth factor receptor (Met/HGF receptor), a transmembrane tyrosine kinase encoded by the MET proto-oncogene, is involved in transformation and invasive behavior of human carcinomas and sarcomas.
|
10867643 |
2000 |
|
Carcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
CUP adenocarcinomas and poorly differentiated carcinomas harboured the highest frequency of variants in genes involved in signal transduction pathways (e.g.MET, EGFR, HRAS, KRAS, and BRAF).
|
29973234 |
2018 |
|
Carcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome.
|
22644302 |
2012 |
|
Carcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
MET overexpression assessed by new interpretation method predicts gene amplification and poor survival in advanced gastric carcinomas.
|
23807774 |
2013 |
|
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
No comprehensive data are available on the molecular predictors of sensitivity to MET inhibitor in lung carcinomas.
|
20736805 |
2010 |
|
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
MET gene amplification correlates with a poor prognosis and poor survival in gastric carcinomas.
|
25820598 |
2015 |